← Back to Search

Antioxidant

MitoQ for Peripheral Arterial Disease

N/A

Recruiting

Research Sponsored by University of Nebraska

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up maximum of 14 minutes on 2 separate days

Awards & highlights

Study Summary

This trial will examine the effects of MitoQ, an antioxidant, on blood flow, skeletal muscle function, and claudication in patients with peripheral artery disease.

Eligible Conditions

Peripheral Arterial Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ maximum of 14 minutes on 2 separate days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~maximum of 14 minutes on 2 separate days

This trial's timeline: 3 weeks for screening, Varies for treatment, and maximum of 14 minutes on 2 separate days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Endothelial Function

Secondary outcome measures

Autonomic nervous system activity

Microvascular function

Nitroglycerin-mediated dilation

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Placebo-MitoQExperimental Treatment1 Intervention

Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.

Group II: MitoQ-PlaceboExperimental Treatment1 Intervention

Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MitoQ

2006

Completed Phase 2

~230

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor

536 Previous Clinical Trials

1,143,909 Total Patients Enrolled

11 Trials studying Peripheral Arterial Disease

491 Patients Enrolled for Peripheral Arterial Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment open to participants who are 30 and up?

"This research endeavour is seeking participants aged 50 or over, but no older than 85."

Answered by AI

Could I potentially participate in this research initiative?

"To be eligible for inclusion in this trial, prospective patients must have peripheral arterial disease and fall within the age range of 50 to 85 years old. 13 individuals are being sought out by the researchers."

Answered by AI

Are recruitment efforts still ongoing for this trial?

"From the clinicaltrials.gov page, this active study has been searching for participants since it was posted on September 5th 2018 and last modified in November 4th 2022."

Answered by AI

How many individuals have registered for participation in this experiment?

"Affirmative. Clinicaltrials.gov holds the information that this trial, which was initially posted on September 5th 2018, is actively looking for enrollees. 13 patients must be recruited from one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

Song-Young Park 2018. "Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03506633.